Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in MRD+ Solid Tumors (UMBRELLA)
NCT06332274Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), soft tissue sarcoma (STS), sponsored by Gustave Roussy. Started Apr 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06332274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332274.